Cargando…
PET imaging of CXCR4 using copper-64 labeled peptide antagonist
Expression of CXCR4 in cancer has been found to correlate with poor prognosis and resistance to chemotherapy. In this study we developed a derivative of the CXCR4 peptide antagonist, T140-2D, that can be labeled easily with the PET isotope copper-64, and thereby enable in vivo visualization of CXCR4...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085282/ https://www.ncbi.nlm.nih.gov/pubmed/21544263 |
_version_ | 1782202613611102208 |
---|---|
author | Jacobson, Orit Weiss, Ido D. Szajek, Lawrence P. Niu, Gang Ma, Ying Kiesewetter, Dale O. Farber, Joshua M. Chen, Xiaoyuan |
author_facet | Jacobson, Orit Weiss, Ido D. Szajek, Lawrence P. Niu, Gang Ma, Ying Kiesewetter, Dale O. Farber, Joshua M. Chen, Xiaoyuan |
author_sort | Jacobson, Orit |
collection | PubMed |
description | Expression of CXCR4 in cancer has been found to correlate with poor prognosis and resistance to chemotherapy. In this study we developed a derivative of the CXCR4 peptide antagonist, T140-2D, that can be labeled easily with the PET isotope copper-64, and thereby enable in vivo visualization of CXCR4 in tumors. T140 was conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono (N-hydroxysuccinimide ester) (DOTA-NHS) to give T140-2D, which contains a DOTA molecule on each of the two lysine residues. (64)Cu-T140-2D was evaluated in vitro by migration and binding experiments, and in vivo by microPET imaging and biodistribution, in mice bearing CXCR4-positive and CXCR4-negative tumor xenografts. T140-2D was labeled with copper-64 to give (64)Cu-T140-2D in a high radiochemical yield of 86 ± 3% (not decay-corrected) and a specific activity of 0.28 - 0.30 mCi/µg (10.36 - 11.1 MBq/µg). (64)Cu-T140-2D had antagonistic and binding characteristics to CXCR4 that were similar to those of T140. In vivo, (64)Cu-T140-2D tended to bind to red blood cells and had to be used in a low specific activity form. In this new form (64)Cu-T140-2D enabled specific imaging of CXCR4-positive, but not CXCR4-negative tumors. Undesirably, however, (64)Cu-T140-2D also displayed high accumulation in the liver and kidneys. In conclusion, (64)Cu-T140-2D was easily labeled and, in its low activity form, enabled imaging of CXCR4 in tumors. It had high uptake, however, in metabolic organs. Further research with imaging tracers targeting CXCR4 is required. |
format | Text |
id | pubmed-3085282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-30852822011-05-02 PET imaging of CXCR4 using copper-64 labeled peptide antagonist Jacobson, Orit Weiss, Ido D. Szajek, Lawrence P. Niu, Gang Ma, Ying Kiesewetter, Dale O. Farber, Joshua M. Chen, Xiaoyuan Theranostics Research Paper Expression of CXCR4 in cancer has been found to correlate with poor prognosis and resistance to chemotherapy. In this study we developed a derivative of the CXCR4 peptide antagonist, T140-2D, that can be labeled easily with the PET isotope copper-64, and thereby enable in vivo visualization of CXCR4 in tumors. T140 was conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono (N-hydroxysuccinimide ester) (DOTA-NHS) to give T140-2D, which contains a DOTA molecule on each of the two lysine residues. (64)Cu-T140-2D was evaluated in vitro by migration and binding experiments, and in vivo by microPET imaging and biodistribution, in mice bearing CXCR4-positive and CXCR4-negative tumor xenografts. T140-2D was labeled with copper-64 to give (64)Cu-T140-2D in a high radiochemical yield of 86 ± 3% (not decay-corrected) and a specific activity of 0.28 - 0.30 mCi/µg (10.36 - 11.1 MBq/µg). (64)Cu-T140-2D had antagonistic and binding characteristics to CXCR4 that were similar to those of T140. In vivo, (64)Cu-T140-2D tended to bind to red blood cells and had to be used in a low specific activity form. In this new form (64)Cu-T140-2D enabled specific imaging of CXCR4-positive, but not CXCR4-negative tumors. Undesirably, however, (64)Cu-T140-2D also displayed high accumulation in the liver and kidneys. In conclusion, (64)Cu-T140-2D was easily labeled and, in its low activity form, enabled imaging of CXCR4 in tumors. It had high uptake, however, in metabolic organs. Further research with imaging tracers targeting CXCR4 is required. Ivyspring International Publisher 2011-04-19 /pmc/articles/PMC3085282/ /pubmed/21544263 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Research Paper Jacobson, Orit Weiss, Ido D. Szajek, Lawrence P. Niu, Gang Ma, Ying Kiesewetter, Dale O. Farber, Joshua M. Chen, Xiaoyuan PET imaging of CXCR4 using copper-64 labeled peptide antagonist |
title | PET imaging of CXCR4 using copper-64 labeled peptide antagonist |
title_full | PET imaging of CXCR4 using copper-64 labeled peptide antagonist |
title_fullStr | PET imaging of CXCR4 using copper-64 labeled peptide antagonist |
title_full_unstemmed | PET imaging of CXCR4 using copper-64 labeled peptide antagonist |
title_short | PET imaging of CXCR4 using copper-64 labeled peptide antagonist |
title_sort | pet imaging of cxcr4 using copper-64 labeled peptide antagonist |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085282/ https://www.ncbi.nlm.nih.gov/pubmed/21544263 |
work_keys_str_mv | AT jacobsonorit petimagingofcxcr4usingcopper64labeledpeptideantagonist AT weissidod petimagingofcxcr4usingcopper64labeledpeptideantagonist AT szajeklawrencep petimagingofcxcr4usingcopper64labeledpeptideantagonist AT niugang petimagingofcxcr4usingcopper64labeledpeptideantagonist AT maying petimagingofcxcr4usingcopper64labeledpeptideantagonist AT kiesewetterdaleo petimagingofcxcr4usingcopper64labeledpeptideantagonist AT farberjoshuam petimagingofcxcr4usingcopper64labeledpeptideantagonist AT chenxiaoyuan petimagingofcxcr4usingcopper64labeledpeptideantagonist |